Alexion Soliris has ultra-orphan pricetag
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alexion's C5 complement inhibitor Soliris (eculizumab) clears FDA March 16 for treatment of the orphan blood disorder paroxysmal nocturnal hemoglubinuria. The biologic carries a wholesale acquisition cost of $389,000 per year. Alexion is launching the product with a treatment support service (titled OneSource) with case managers to help facilitate reimbursement. During a March 26 conference call, President David Keiser maintained that "this cost is comparable to the cost of other medicines for disabling and life-threatening ultra-orphan diseases, which are often dosed by weight." Alexion, however, is not resting on its laurels with the PNH claim: the firm is running the EXPLORE patient identification program for blood cell production disorders and recently said it is considering a similar program for the thrombosis market (1Pharmaceutical Approvals Monthly March 2007, p. 4)...
You may also be interested in...
Alexion Aims To Drive PNH Diagnoses (And Soliris Sales) With Diagnostic
Alexion believes the challenge of identifying new patients with the "ultra-orphan" blood disorder paroxysmal nocturnal hemoglobinuria who are candidates for the company's biologic Soliris (eculizumab) will be helped by diagnostic technology recently in-licensed by the firm
Alexion Eyes Thrombosis Market For Next Soliris Patient Identification Push
Alexion is considering running a new program in the thrombosis market to identify potential paroxysmal nocturnal hemoglobinuria patients for Soliris, along the lines of the firm's ongoing EXPLORE diagnostics program looking for PNH in the bone marrow failure setting
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.